A sweet surprise for HIV broadly neutralizing antibodies.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Virological features associated with the development of broadly neutralizing antibodies to HIV-1.Trends in microbiology · 2015
   Review
2. Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection.Current opinion in HIV and AIDS · 2014
   Review
3. HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study.PloS one · 2014
   Article

Corrections and comments

• Comment on
  Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.2012

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as